[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asphyxia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asphyxia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100645456","multimodal-analysis-of-early-biomarkers-of-the-impacts-of-perinatal-asphyxia-100645456",false,"NCT07702500","Multimodal Analysis of Early Biomarkers of the Impacts of Perinatal Asphyxia","Neurobiom","Inclusion Criteria:\n\n* Non-Perinatal Asphyxia Cohort:\n\nThe non-PA cohort includes:\n\n* Full-term infants (born between 36 and 42 weeks of gestation), clinically \"normal\" and without PA. Infants must have birth weights within the normal range for their gestational age.\n* Satisfactory Apgar scores at 1, 3, and 5 minutes, indicating good health.\n* Meet specific biochemical biomarker criteria as defined by the study protocols.\n* No major complications should occur during pregnancy or delivery.\n\n  * At-Risk Perinatal Asphyxia Cohort:\n\nThe at-risk PA cohort includes newborns who are:\n\n* Identified by healthcare professionals as being at risk based on criteria that do not exceed the diagnostic thresholds for PA but whose combined assessment of maternal, fetal, and neonatal medical criteria suggests risk factors and early signs of potential PA,\n* OR\n* Classified as such based on biochemical markers identified in WP1 (see WP1).\n\n  * Confirmed Perinatal Asphyxia Cohort:\n\nThe PA cohort includes:\n\n* Newborns diagnosed with PA and treated with hypothermia. The inclusion criteria for this group allow for various modes of delivery, complications during pregnancy and delivery, and a range of gestational ages, as long as they meet the criteria for PA.\n* Birth weight must be ≥ 1800 g.\n* Apgar scores at 1, 3, and 5 minutes must indicate potential complications or difficulties.\n* Specific biochemical markers indicative of PA must be present\n\nExclusion Criteria:\n\n* Full-term newborn not meeting inclusion criteria",true,"ALL","1 Day",{"count":20,"type":21},280,"ESTIMATED","INTERVENTIONAL",[24],"NA","Current diagnostic methods rely primarily on clinical symptoms, supplemented by brain imaging and physiological tests. However, these signs of injury only become apparent once significant damage has occurred, thus delaying intervention and compromising the effectiveness of treatments. Therefore, there is a need to develop new markers to develop preventive measures for the consequences of perinatal asphyxia.\n\nThe primary objective is to compare cognitive and motor development at 18 months in three populations (PA, at risk of PA, and Control) defined on the basis of clinical, biological, and neural criteria.",[27,28,29,30,31],"Neonate","Asphyxia","EEG","Eye Tracking","Biomarkers",[27,33,34,29,35,31],"asphyxia","anoxo ischemia","Eye tracking","NOT_YET_RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-14","ACTUAL",{"date":42,"type":21},"2026-07",{"date":44,"type":21},"2029-12",{"name":46,"class":47},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":48},"100503542","phase-4-hydrocortisone-therapy-optimization-during-hypothermia-treatment-in-asphyxiated-neonates-100503542","NCT05836610","Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates","Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates - a Pharmacokinetic Study","UniCort","Inclusion Criteria:\n\n* gestational age ≥ 36 weeks\n* provision of whole-body hypothermia treatment (as described by Azzopardi et al.)\n* presence of systemic hypotension (defined as a mean arterial pressure less than the gestational age in weeks)\n* indication for hydrocortisone treatment during hypothermia by the attending physician\n* indwelling arterial catheter to take blood samples without additional painful punctures: umbilical arterial catheter or peripheral arterial catheter\n* written informed parental consent\n\nExclusion Criteria:\n\n* infants who are expected to be \\> 6 hours of age (not suitable for cooling)\n* critical congenital abnormalities\n* genetic disease\n* signed informed consent is unavailable","72 Hours",{"count":59,"type":21},50,[61],"PHASE4","This is a prospective, single center, pharmacokinetic study of intravenous hydrocortisone therapy for systemic low blood pressure during hypothermia treatment in asphyxiated newborns. Patients will be allocated to hydrocortisone supplementation while receiving conventional inotropic therapy as needed.\n\nThe hypothesis is that a detailed study of hydrocortisone pharmacokinetics during therapeutic hypothermia would help to personalize steroid supplementation in asphyxiated neonates. As the overall metabolic rate decreases with lower body temperature, drug metabolism is likely to be reduced as well, and lower doses, or less frequent dosing will be sufficient to achieve the targeted steroid range and biological effects in asphyxiated neonates with relative adrenal insufficiency. Thus, the investigators are planning to measure initial, baseline serum cortisol levels and serial serum cortisol levels after hydrocortisone supplementation in cooled asphyxiated neonates.",[64,28,65,66],"Hypoxic-Ischemic Encephalopathy","Hypotension","Circulatory Failure Neonatal",[68,69,70,71,64,28],"Hypothermia treatment","Relative adrenal insufficiency","Hydrocortisone supplementation","Hydrocortisone pharmacokinetics","RECRUITING","2026-04-23",{"date":75,"type":40},"2026-04-28",{"date":77,"type":40},"2021-09-21",{"date":79,"type":21},"2027-09",{"name":81,"class":47},"Semmelweis University",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":16,"sex":17,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":103,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":48},"100565751","neodoppler-new-ultrasound-technology-for-continuous-monitoring-of-cerebral-circulation-pilot-100565751","NCT06646250","NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot","NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Blood Flow in Infants","CE-NeoDoppler","Inclusion Criteria:\n\n* Open fontanelle\n* Healthy preterm or term born neonates\n* Neonates with a medical condition of interest according to the different cohort studies: patent ductus arteriosus, perinatal asphyxia, stroke, pulmonary hypertension, congenital heart condition or infection\u002Fsepsis\u002Fmeningitis\n* Neonates in need of procedures\n\nExclusion Criteria:\n\n* Caregivers not understanding\u002Fspeaking Norwegian or English\n* Caregivers not giving their consent","0 Minutes","12 Months",{"count":93,"type":21},180,"OBSERVATIONAL","Non-invasive tools for monitoring of course of disease are important and necessary in the treatment of pre-term\u002Fpremature infants and sick neonates. For many years, the ultrasound group in Trondheim has been at the forefront in the development of new ultrasound technology for the diagnosis and monitoring of disease. Several methods previously developed in this research group are today widely used in hospitals around the world. In this project the investigators aim to test a new ultrasound technology that allows continuous monitoring of cerebral blood flow in sick neonates and pre-term children. This technology was CE-certified in October 2022, and in this project the investigators will test the CE-certified version with the newest available approved software.",[97,98,99,28,100,101,102],"Preterm","Patent Ductus Arteriosus","Sepsis","Stroke","Pulmonary Hypertension","Congenital Heart Disease",[104,105,106,27],"Cerebral Doppler","Monitoring","Continuous","2026-04-22",{"date":73,"type":40},{"date":110,"type":40},"2024-10-20",{"date":112,"type":21},"2029-12-31",{"name":114,"class":47},"St. Olavs Hospital"]